Johannes Vermeerplain 9-1
491 articles with QIAGEN N.V.
Sysmex Inostics, Inc. and QIAGEN N.V. will co-exhibit at the 2022 ASCO Annual Meeting, the world's largest clinical cancer research meeting, held June 3, 2022, through June 7, 2022, in Chicago.
U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infectious Diseases – Including COVID-19 Outbreaks
QIAGEN N.V. announced that it welcomed an endorsement from the National Wastewater Surveillance System of the U.S. Centers for Disease Control and Prevention and their validation and approval for the use of two digital PCR systems – including the QIAcuity digital PCR system – for wastewater surveillance of 30 pathogens, including the SARS-CoV-2 virus.
QIAGEN N.V. announced that its recently launched, environmentally friendlier QIAwave nucleic-acid extraction kits have received the prestigious ACT Environmental Impact Factor Label from My Green Lab, a non-profit organization dedicated to advancing sustainability in scientific research.
QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels
QIAGEN N.V. announced the launch of QIAstat-Dx Rise – a high-capacity version of the QIAstat-Dx automated syndromic system – and enhancements to the menu of tests for the fully integrated one-step molecular testing solution that provides results in about one hour.
QIAGEN N.V. announced that it has signed agreements to acquire a 96% majority ownership stake in BLIRT SA, a manufacturer of recombinant enzymes for the life science industry based in Gdansk, Poland.
QIAGEN N.V. announced the proposal of Dr. Eva Pisa, a leader in health diagnostics and biotechnology who has extensive experience from start-ups to corporate companies, as a new member of the Supervisory Board.
QIAGEN N.V. announced that its NeuMoDx HSV 1/2 Quant Assay for the quantification and differentiation of herpes simplex virus type 1 DNA and/or herpes simplex virus type 2 has received CE-IVD certification for the European Union and other countries that accept this marking.
QIAGEN exceeds outlook for Q1 2022, delivers strong 14% CER sales growth from non-COVID products and increases full-year outlook
QIAGEN N.V. announced results for the first quarter of 2022 and increased the outlook for full-year 2022.
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release results for the first quarter of 2022 on Wednesday, April 27, at approximately 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
QIAGEN N.V. marked World TB Day by announcing its QuantiFERON blood test has been used to screen patients for tuberculosis infection more than 100 million times since its launch – an achievement that cements its status as the gold standard in the fight against this contagious and often deadly disease.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2021, with the U.S. Securities and Exchange Commission.
QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation
QIAGEN N.V. announced that its QuantiFERON tuberculosis testing solution has gained additional momentum with the approval of the fourth generation of this modern gold standard test in China and a new endorsement from the World Health Organization.
QIAGEN Completes U.S. Federal Contract to Equip Local Public Health Authorities with QIAcuity Digital PCR System for COVID-19 Surveillance
QIAGEN N.V. announced it has completed a U.S. government contract to equip public health laboratories across the country with the QIAcuity digital PCR system to monitor the spread of the COVID-19 pandemic by testing wastewater for the presence of SARS-CoV-2 pathogens.
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the fourth quarter and full-year results of 2021 on Tuesday, February 8, at approximately 16:05 Eastern Standard Time (EST)
QIAGEN N.V. announced its new QIAwave product line by launching three nucleic acid extraction kits that use fewer components and produce less waste than existing ones.
QIAGEN expands QIAstat-Dx syndromic testing menu and announces launch plans for new QIAstat-Dx Rise higher-throughput version
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced important enhancements in the commercialization of its QIAstat-Dx syndromic testing solution – which enables laboratories and hospitals worldwide to test patients for multiple pathogens from one sample – with new tests and the launch of a higher-throughput version that includes a new level of walk-away efficiency through the new QIAstat-Dx Smart Drawer.
QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations
QIAGEN N.V. announced new additions to the growing number of applications for QIAcuity, its ultrasensitive digital PCR platform that has set new standards by using so-called nanoplates to process samples in two hours rather than the five hours required by other systems.
QIAGEN N.V. announced important expansion initiatives for its QuantiFERON franchise, building on its status as the gold standard for detection of tuberculosis, while developing new applications for this technology designed to detect potentially deadly latent diseases.
QIAGEN N.V. announced the CE marking of its QuantiFERON® SARS-CoV-2 assay that measures T-cell responses to SARS-CoV-2 and aids in the assessment of immunity in individuals who have received COVID-19 vaccination.
QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in light of the new coronavirus variant B.1.1.529
QIAGEN N.V. announced its polymerase chain reaction tests remain accurate and effective in detecting SARS-CoV-2 infections in light of the emergence of a new variant of concern detected in South Africa.